Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results".
作者信息
Mühlbacher Axel C, Sadler Andrew
机构信息
Health Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany.
Gesellschaft für Empirische Beratung GmbH (GEB), Freiburg, Germany.
出版信息
PLoS One. 2021 Feb 18;16(2):e0245480. doi: 10.1371/journal.pone.0245480. eCollection 2021.
Abstract
摘要
相似文献
1
Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results".关于论文《索磷布韦在德国丙型肝炎基因1型感染治疗中的成本效益：已发表结果的重新分析》的评论
PLoS One. 2021 Feb 18;16(2):e0245480. doi: 10.1371/journal.pone.0245480. eCollection 2021.
2
Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.德国 1 型丙型肝炎病毒感染者使用索非布韦的成本效益：已发表结果的重新分析。
PLoS One. 2020 Oct 2;15(10):e0236543. doi: 10.1371/journal.pone.0236543. eCollection 2020.
3
Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.通用泛基因型索磷布韦/维帕他韦与基于基因型的直接作用抗病毒药物治疗丙型肝炎的成本效益比较。
J Gastroenterol Hepatol. 2018 Dec;33(12):2029-2036. doi: 10.1111/jgh.14301. Epub 2018 Jun 25.
4
What is the role of sofosbuvir in treating hepatitis C infection?索非布韦在治疗丙型肝炎感染中起什么作用？
JAAPA. 2015 Feb;28(2):16-9. doi: 10.1097/01.JAA.0000459818.09661.c0.
5
Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir.索磷布韦和维帕他韦治疗基因 7 型丙型肝炎病毒感染患者。
Hepatology. 2016 Sep;64(3):983-5. doi: 10.1002/hep.28636. Epub 2016 Jun 14.
6
A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.终章：肝移植中丙型肝炎病毒3型的消除；索磷布韦/达卡他韦在难治性人群中的应用
Exp Clin Transplant. 2018 Feb;16(1):61-67. doi: 10.6002/ect.2016.0296. Epub 2017 Nov 15.
7
Hepatitis C Virus Genotype 8 Infection-Successful Treatment With Sofosbuvir/Velpatasvir.丙型肝炎病毒8型感染——索磷布韦/维帕他韦治疗成功案例
J Infect Dis. 2019 Jul 19;220(4):720-722. doi: 10.1093/infdis/jiz155.
8
Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?索磷布韦与达拉他韦联合利巴韦林或不联合利巴韦林治疗 1 型和 2 型丙型肝炎病毒：在低收入国家，泛基因型治疗的一种可能替代方案？
Int J Infect Dis. 2021 Jun;107:166-169. doi: 10.1016/j.ijid.2021.04.061. Epub 2021 Apr 22.
9
Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure.索磷布韦、聚乙二醇干扰素和利巴韦林用于索磷布韦和来迪帕司韦治疗失败后的丙型肝炎病毒1b型再治疗。
Hepatology. 2018 May;67(5):2049-2050. doi: 10.1002/hep.29667. Epub 2018 Mar 25.
10
Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection.索磷布韦加达拉他韦作为2型丙型肝炎病毒感染的血液透析患者的替代治疗方案。
Enferm Infecc Microbiol Clin (Engl Ed). 2018 Aug-Sep;36(7):457. doi: 10.1016/j.eimc.2017.10.012. Epub 2017 Dec 6.
本文引用的文献
1
Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.德国 1 型丙型肝炎病毒感染者使用索非布韦的成本效益：已发表结果的重新分析。
PLoS One. 2020 Oct 2;15(10):e0236543. doi: 10.1371/journal.pone.0236543. eCollection 2020.
2
Check Your Checklist: The Danger of Over- and Underestimating the Quality of Economic Evaluations.检查你的清单：高估和低估经济评估质量的风险。
Pharmacoecon Open. 2019 Dec;3(4):433-435. doi: 10.1007/s41669-019-0118-3.
3
[The Probabilistic Efficiency Frontier: A Value Assessment of Treatment Options in Hepatitis C].[概率效率前沿：丙型肝炎治疗方案的价值评估]
Gesundheitswesen. 2019 Jan;81(1):e21-e32. doi: 10.1055/s-0043-107235. Epub 2017 Jun 19.
4
The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options.概率效率前沿：德国成本效益分析框架在丙型肝炎治疗方案中的实际应用
Value Health. 2017 Feb;20(2):266-272. doi: 10.1016/j.jval.2016.12.015. Epub 2017 Feb 16.
5
First and Foremost Battle the Virus: Eliciting Patient Preferences in Antiviral Therapy for Hepatitis C Using a Discrete Choice Experiment.首要任务：对抗病毒——利用离散选择实验了解丙型肝炎抗病毒治疗中的患者偏好
Value Health. 2016 Sep-Oct;19(6):776-787. doi: 10.1016/j.jval.2016.04.007.
6
Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment.慢性丙型肝炎抗病毒治疗的偏好：一项离散选择实验。
Eur J Health Econ. 2017 Mar;18(2):155-165. doi: 10.1007/s10198-016-0763-8. Epub 2016 Feb 4.
7
Making Good Decisions in Healthcare with Multi-Criteria Decision Analysis: The Use, Current Research and Future Development of MCDA.运用多标准决策分析在医疗保健领域做出明智决策：多标准决策分析的应用、当前研究与未来发展
Appl Health Econ Health Policy. 2016 Feb;14(1):29-40. doi: 10.1007/s40258-015-0203-4.
8
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.一致性健康经济评估报告标准（CHEERS）声明。
BMC Med. 2013 Mar 25;11:80. doi: 10.1186/1741-7015-11-80.
Zotero 插件